J&J restructures pharma supply chain, offloading sites as part of $55 B U.S. manufacturing push

Johnson & Johnson announced it is restructuring its pharmaceutical supply chain, offloading certain sites to streamline operations as part of its $55 billion U.S. manufacturing initiative.

The changes, disclosed in the Q2 earnings release, are projected to cost up to $750 million and are slated for completion by fiscal year 2029. The company has already recorded $200 million in restructuring expenses for the second quarter of 2026, primarily from asset impairments.

The broader investment also includes a $1 billion commitment to expand manufacturing capacity for vision products, packaging and distribution capabilities.

J&J raised its outlook for the year, reporting second‑quarter sales growth of 6.6% compared with the same period in 2025.